Skip to main content
. 2018 Jul 28;109(9):2781–2791. doi: 10.1111/cas.13715

Figure 4.

Figure 4

Effects of the treatment with the AKT kinase inhibitor AZD 5363 (1 μmol/L), the mammalian target of rapamycin (mTOR) inhibitor everolimus (10 nmol/L), the mTOR activator MHY 1485 (2 μmol/L), and the signal transducer and activator of transcription (STAT)3 inhibitor 5,15‐diphenylporphyrin (5,15‐DPP; 10 μmol/L) on expression levels of human epidermal growth factor receptor 2 (HER2) transcripts (for 24 h) and proteins (for 48 h) in MDA‐MB‐453 cells. A‐D, Real‐time PCR assay for HER2 in AZD 5363‐ (A), everolimus‐ (B), MHY 1485‐ (C), and 5,15‐DPP‐treated MDA‐MB‐453 cells (D) (n = 4 for each). Expression levels are expressed as a ratio to β‐actin (ACTB). E‐H, Protein lysates of AZD 5363‐ (E), everolimus‐ (F), MHY 1485‐ (G), and 5,15‐DPP‐treated MDA‐MB‐453 cells (H) were probed by immunoblotting with anti‐HER2 (upper panel) and anti‐ACTB (lower panel) antibodies on the same filter. After compensation, the HER2 signal in the vehicle control was expressed as 1.0 (n = 4 for each). Results are expressed as means ± SEM. *,**P < .05, .01 vs the vehicle control